[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests]
Publisher DOI
PubMed ID
23117668
Abstract
New oral anticoagulants promise to overcome essential drawbacks of traditional substances. They have a predictable therapeutic effect, a wide therapeutic window, only limited interaction with food and drugs and can be administered p.o. with a fixed dose. On the other hand, knowledge on the laboratory management of new anticoagulants is limited. In the present article we discuss possible indications and available assays for monitoring of Rivaroxaban, Apixaban and Dabigatran. Furthermore, we discuss interpretation of routine coagulation tests during therapy with these new drugs.
Date Issued
2012
Publication Type
Article
Language(s)
de
Author(s)
Additional Credits
Journal
Therapeutische Umschau
Publisher
Huber
ISSN
0040-5930
Access(Rights)
metadata.only